ADIPOQ

Across TCGA pan-cancer cohorts, ADIPOQ mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ADIPOQ data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADIPOQ mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADIPOQ expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ADIPOQ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.298	0.578	.006	32	view →
CCRCC	OS	Median	III,IV	0.860	0.531	.009	25	view →
HNSC	DFS	Median	III,IV	0.920	0.691	.001	15	view →
UCEC	OS	Tertile	III,IV	0.282	1.000	.022	8	view →
LSCC	DFS	Median	II,III,IV	0.830	1.000	.003	7	view →
GBM	OS	Median	All	0.532	0.240	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ADIPOQ–PDAC (OS)

Open the PDAC breakdown →